Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XIN5494
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
01
Overview
XIN5494 is a preclinical small molecule inhibitor of MAPK-activated protein kinase 2 (MK2), originally developed by XinThera and subsequently acquired by Gilead Sciences. MK2 is a downstream effector of the p38 MAPK pathway and plays a critical role in the post-transcriptional regulation of pro-inflammatory cytokines, including TNF-alpha, IL-1 beta, and IL-6. By targeting MK2, XIN5494 is designed to provide a potent anti-inflammatory effect while potentially avoiding the side effects associated with direct p38 MAPK inhibition. The drug is being investigated for the treatment of various inflammatory and autoimmune conditions, such as rheumatoid arthritis.
02
Targets
MK2 (Mitogen-activated protein kinase-activated protein kinase 2)
Beyond the preview
Go deeper on XIN5494.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XIN5494.